Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial

Immunogenicity and safety following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine with Matrix-MTM adjuvant (NVX-CoV2373) versus a primary series in people living with and without HIV-1 infection in South Africa: A randomized crossover phase 2a/2b trial

COVID-19 remains a global public health issue and an improved understanding of vaccine performance in immunocompromised individuals, including people living with HIV (PLWH), is needed. Initial data from the present study’s pre-crossover/booster phase were previously reported. This phase 2a/b clinica...

Full description

Saved in:

Bibliographic Details
Main Authors:	Vivek Shinde, Anthonet Lombard Koen, Zaheer Hoosain, Moherndran Archary, Qasim Bhorat, Lee Fairlie, Umesh Lalloo, Mduduzi S. L. Masilela, Dhayendre Moodley, Sherika Hanley, Leon Frederik Fouche, Cheryl Louw, Michele Tameris, Nishanta Singh, Ameena Goga, Keertan Dheda, Coert Grobbelaar, Natasha Joseph, Johan J. Lombaard, Rosie Mngqibisa, As’ad Ebrahim Bhorat, Gabriella Benadé, Natasha Lalloo, Anna Pitsi, Pieter-Louis Vollgraaff, Angelique Luabeya, Aliasgar Esmail, Friedrich G. Petrick, Aylin Oommen Jose, Sharne Foulkes, Khatija Ahmed, Asha Thombrayil, Dishiki Kalonji, Shane Cloney-Clark, Mingzhu Zhu, Chijioke Bennett, Gary Albert, Alex Marcheschi, Joyce S. Plested, Susan Neal, Gordon Chau, Iksung Cho, Louis Fries, Greg M. Glenn, Shabir A. Madhi
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2024-12-01
Series:	Human Vaccines & Immunotherapeutics
Subjects:	Novavax, Inc. the Bill & Melinda Gates Foundation and the Coalition for Epidemic Preparedness Innovations
Online Access:	https://www.tandfonline.com/doi/10.1080/21645515.2024.2425147
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Structural serology of polyclonal antibody responses to mRNA-1273 and NVX-CoV2373 COVID-19 vaccines
by: Sandhya Bangaru, et al.
Published: (2025-07-01)

Nuvaxovid NVX-CoV2373 vaccine safety profile: real-world data evidence after 100,000 doses, Australia, 2022 to 2023
by: Jim P Buttery
Published: (2024-12-01)

COVID-19 Vaccines Effectiveness and Safety in Trinidad and Tobago: A Systematic Review and Meta-Analysis
by: Angel Justiz-Vaillant, et al.
Published: (2025-01-01)

Safety and Immunogenicity of Pfizer BioNTech mRNA Vaccine and Novavax NVX-CoV2373 COVID-19 Mix and Match Booster Vaccination in Adolescents Aged 12-17 Years with HIV infection in Kenya
by: Dr Lucas Tina, et al.
Published: (2025-03-01)

Professionalisation experiences of a ‘business-minded’ HIV targeted intervention NGO in India: An organisational ethnography
by: Anuprita Shukla, et al.
Published: (2024-12-01)

Evaluation of the MAScIR SARS-CoV-2 M Kit 2.0 on the SARS-CoV-2 Infection
by: Amal Zouaki, et al.
Published: (2023-01-01)

Susceptibility of swine cells and domestic pigs to SARS-CoV-2
by: David A. Meekins, et al.
Published: (2020-01-01)

SARS-CoV-2 Neutralizing Antibodies 2.0
by: Youchun Wang
Published: (2024-11-01)

Chronocoulometric Quantum Dot Aptasensor for SARS‐CoV‐2 Nucleocapsid Protein Biomarker
by: Nelia A. Sanga, et al.
Published: (2024-07-01)

A quantitative model used to compare within-host SARS-CoV-2, MERS-CoV, and SARS-CoV dynamics provides insights into the pathogenesis and treatment of SARS-CoV-2.
by: Kwang Su Kim, et al.
Published: (2021-03-01)

Caregiver perspectives on the long-lasting impact of the COVID-19 pandemic on children with cerebral palsy in Johannesburg, South Africa
by: Skye Nandi Adams, et al.
Published: (2024-08-01)

The Intersection of SARS-CoV-2 and Diabetes
by: Jacob H. Nichols, et al.
Published: (2025-06-01)

The olfactory bulb - gateway for SARS-Cov-2?
by: Jovanović Aleksandar, et al.
Published: (2022-01-01)

Vaccination against SARS-COV‑2 in oncology
by: A. A. Polyakov, et al.
Published: (2021-06-01)

In-silico Immunomodelling of SARS-CoV-2
by: Amirhosein Maali, et al.
Published: (2021-06-01)

SARS-COV-2 INFECTION AND THYROID DISEASES
by: Özlem Çelik
Published: (2021-09-01)

SARS-CoV-2 associated encephalitis
by: Jasmina Poluga, et al.
Published: (2025-05-01)

SARS-COV-2 INFLUENCES IN HOSPITAL FUNDING
by: Sebastian MEZEI
Published: (2023-12-01)

Stability of SARS-CoV-2 phylogenies.
by: Yatish Turakhia, et al.
Published: (2020-11-01)

Susceptibility of rabbits to SARS-CoV-2
by: Anna Z. Mykytyn, et al.
Published: (2021-01-01)

SARS-CoV-2-Neutralizing Antibodies
by: Yawen Liu, et al.
Published: (2024-11-01)

SARS-CoV-2 Alchemy: Understanding the dynamics of age, vaccination, and geography in the evolution of SARS-CoV-2 in India.
by: Mansi Patel, et al.
Published: (2025-03-01)

Risk factors and effectiveness of vaccination for nosocomial SARS-CoV-2 acquisition throughout the SARS-CoV-2 pandemic
by: Nishi Dave, et al.
Published: (2025-08-01)

SARS-CoV-2 spike S2-specific neutralizing antibodies
by: Chia-Jung Li, et al.
Published: (2023-12-01)

Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants.
by: Catherine Riou, et al.
Published: (2024-01-01)

Experimental re-infected cats do not transmit SARS-CoV-2
by: Natasha N. Gaudreault, et al.
Published: (2021-01-01)

Enfisema subcutáneo y neumomediastino en un paciente con infección por SARS-COV-2: SEPIM-SARS-COV-2
by: Jesica Naanous-Rayek, et al.
Published: (2024-01-01)

Validation of the Diabetomics CovAB SARS-CoV-2 antibody test in children: comparison with serology
by: Manisha Gurumurthy, et al.
Published: (2024-11-01)

Electromagnetic waves destabilize the SARS-CoV-2 Spike protein and reduce SARS-CoV-2 Virus-Like particle (SC2-VLP) infectivity
by: Christina Pantoja, et al.
Published: (2025-05-01)

Macrovascular Function in People with HIV After Recent SARS-CoV-2 Infection
by: Ana S. Salazar, et al.
Published: (2025-01-01)

A Benchmark of methods for SARS-CoV-2 whole genome sequencing and development of a more sensitive method
by: Anthony Bayega, et al.
Published: (2025-08-01)

SARS-CoV-2 Detection From Voice
by: Gadi Pinkas, et al.
Published: (2020-01-01)

Racing for a SARS‐CoV‐2 vaccine
by: Özlem Türeci, et al.
Published: (2021-09-01)

Clinical Traits of SARS-CoV-2 Infection
by: O. Yu. Zolnikova, et al.
Published: (2020-12-01)

SARS-COV-2 mutations in North Rift, Kenya
by: Elius Mbogori, et al.
Published: (2025-01-01)

Monitoring and assessment of SARS-CoV-2 evolution
by: V. V. Miasoiedov, et al.
Published: (2022-02-01)

Lactancia materna y SARS-CoV-2
by: Gilberto Bastidas-Pacheco, et al.
Published: (2022-05-01)

The prospects for the SARS‐CoV‐2 pandemic in Africa
by: Virginia Quaresima, et al.
Published: (2020-05-01)

Pneumothorax and Pneumomediastinum in SARS-CoV-2 Infection
by: Cătălina Aldea, et al.
Published: (2025-06-01)

Myocardial Damage in SARS-CoV-2 Infection
by: Elizabeth Sellén Sanchén, et al.
Published: (2020-11-01)